ESMO 2018: nearly 50 Institut Curie colleaguess in attendance
ESMO’s annual congress is a major highlight in Europe’s oncology calendar. Every year, Institut Curie colleagues attend the event to present their most recent findings. This year is set to be particularly active, with presentations and posters covering many of Institut Curie’s flagship fields, including immunotherapy, breast cancer, childhood cancer, lung cancer, epigenetics and early clinical trials, among others.
Get real-time articles and educational videos explaining the results of the main presentations on this page. And follow us live on Twitter: @Institut_Curie #ESMO18
Key highlights:
- “Testing BRCA mutations: who, when and how” - Prof. Dominique Stoppa-Lyonnet – Friday 19 October – 2:00pm
- "Phase II/III trial on radiotherapy-activated hafnium nanoparticles” - Dr. Sylvie Bonvalot – Friday 19 October – 2:24pm
- “Therapeutic potential of extra-cellular vesicles and exosomes in cancer” - Clotilde Théry – Friday 19 October – 4:25pm
- “Thymus tumors: emerging systemic treatment options” - Prof. Nicolas Girard – Saturday 20 October – 8:00am
- “Epigenetics in Ewing sarcomas” - Dr. Olivier Delattre – Saturday 20 October – 4:35pm
- “The role played by sequencing in developing therapies” - Prof. Christophe Le Tourneau – Monday 22 October – 9:30am
- “New radiation techniques” - Prof. Philip Poortmans – Monday 22 October – 3:20pm
BRCA genes : new applications and new precautions
An innovative cancer treatment reveals new uses in understanding alterations in BRCA genes in some patients. Yet as Pr Dominique Stoppa-Lyonnet, head of Institut Curie’s genetics department and professor at Paris-Descartes University will explain at the ESMO congress in Munich on 19 October, these patients must be given the right information and support. More information
Clinical trial : promising results for boosting the effects of radiotherapy
The goal behind the international phase III trial promoted by Nanobiotix* was to potentiate the action of radiotherapy by using hafnium nanoparticles, with Dr. Sylvie Bonvalot serving as the principal investigator and coordinator. And the goal was accomplished with flying colors based on the initial findings presented at the ESMO congress. More information on the clinical trial
Lung cancer: profiling patients for tailored treatments
A study by Dr. Emanuela Romano at Institut Curie aims to identify the patients most likely to benefit from immunotherapy for non-small cell lung cancer.
Epigenetic insights into Ewing sarcoma
Ewing tumors imply genetic alterations that in turn imply epigenetic modifications. Olivier Delattre, a specialist in this type of cancer at Institut Curie, will be speaking at the ESMO congress to invite the scientific and medical community to delve deeper into this subject.
Tumor sequencing for access to new medication
Four years ago, Institut Curie was one of the first establishments to offer patients access to a multidisciplinary molecular consultation meeting (RCP) (MCM). On 22 October, Prof. Christophe Le Tourneau will present the meeting’s working methods and benefits at the ESMO congress.
Bone metastases: precision rays thanks to stereotaxie
Used to fight some forms of bone metastases, radiotherapy may significantly improve patients’ quality of life. Prof. Philip Poortmans, Head of the Oncology/Radiotherapy Department at Institut Curie, will share current approaches in the field with colleagues at the ESMO congress. More information
Sur place : venez nous rendre visite sur le stand 270 !